New Delhi: The Drugs Controller General of India (DCGI) has approved the Restricted Emergency Use Authority (EUA) of Bharat Biotech’s Covid-19 vaccine Coxavin for children 6-12 years old and Biological E. K Corbevax is approved. years age group.
This granted Cadila emergency use authorization for an additional dose of 3mg for its ZyCoV-D on a two-jab schedule of 28 days apart for people over the age of 12.
The move comes amid a fresh increase in daily Covid cases in India, with most pandemic-induced restrictions easing and schools reopening.
As of now, Corbevax is the only vaccine permitted for children 12-14 years of age, while Serum Institute’s Kovovax is for children 12-17 years old. More than 2.70 crore first dose shots have been given to children in the age group of 12 to 14 years.
Hyderabad-based Biological E’s Corbevax is a “recombinant protein sub-unit” vaccine, which is made of spike proteins on the surface of the virus, and helps the body develop immunity to infection, while Bharat Biotech’s Coxvin is an indigenous , is an inactivated vaccine. ,
Last Thursday, Mint reported that the expert panel of DCGI discussed covid vaccine, EUA recommended for Corbevax. It had sought more submissions from Bharat Biotech for its vaccine for children.
in the fight against coronavirus Epidemic, vaccination has played an important role. India started its vaccination campaign in phases on 16 January 2020. So far more than 187.95 crore doses have been given to the eligible population.
Health workers, frontline workers and 2,69,76,618 people in the category of elderly people above 60 years of age have also received booster, or precaution, doses.
The central government has provided over 1.92 billion vaccine doses to states and union territories, of which 201 million are still available with the states.